Insilico Medicine 和 Human Longevity 已达成合作，将开发旨在提前数十年预测疾病的 AI 基础模型。此次合作结合了 Insilico 的 AI 算法和 Human Longevity 的基因组数据，以推进个性化健康研究。该项目瞄准了价值数万亿美元的蓬勃发展的全球长寿市场。 AI
影响 此次合作有望加速 AI 驱动的个性化医疗和药物发现的开发。
排序理由 这是两家公司为特定应用开发 AI 模型而进行的合作，并非前沿模型发布或行业范围内的重大事件。
AI 生成摘要 · Google Gemini · 来自 2 个来源。 我们如何撰写摘要 →
Hong Kong-listed artificial intelligence drug-discovery company Insilico Medicine has struck a collaboration with US-headquartered Human Longevity to co-develop what they describe as “the industry’s first large-scale” AI foundation models capable of predicting diseases – such as …
Insilico Medicine, the Hong Kong-listed AI drug discovery company, has teamed up with US-based Human Longevity to build what they call the industry first large-scale AI foundation models capable of predicting diseases like cancer decades before clinical symptoms appear. The partn…